Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - metforminhydrochlorid, sitagliptin - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - metforminhydrochlorid, sitagliptinhydrochlorid - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glenmark arzneimittel gmbh - metforminhydrochlorid, sitagliptinhydrochlorid - filmovertrukne tabletter - 50+850 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm generics a/s - metforminhydrochlorid - filmovertrukne tabletter - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - metforminhydrochlorid - filmovertrukne tabletter - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - metforminhydrochlorid - filmovertrukne tabletter - 1000 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medical valley invest ab - metforminhydrochlorid - filmovertrukne tabletter - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - metforminhydrochlorid - filmovertrukne tabletter - 500 mg